{
  "docId": "019de070-5095-745c-b54c-b78e5ae1b904",
  "docSlug": "0dc8a543e5d2136d106b59f85712c2a9",
  "documentTitle": "Taysha | IPO Presentation Deck | 66 slides",
  "authorId": "taysha",
  "authorName": "Taysha Gene Therapies",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 66,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The slide compares TSHA-102 against control and other AAV9 constructs. The bottom box highlights specific adverse event rates (lesions/prolapses).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-5095-745c-b54c-b78e5ae1b904/35",
  "deckHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904",
  "deckJsonHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904.json",
  "deckAnchorHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.3,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Mice were dosed P28-35",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d312b07-2106-4c2a-83aa-09a131d4d1f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.65,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Aggregate behavioral scores over 34 weeks",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2876fe4b-867f-4e5b-b64c-b993a179b345",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.75,
        "y": 0.2
      },
      "kind": "legend",
      "text": "Legend for treatment groups and n-values",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d92dc0f-a249-4adc-8f09-d9b3fd602a8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "list",
      "text": "12% (3/24) of AAV9/mini-treated WT mice developed lesions and prolapses; 0% (0/24) of AAV9/miRARE-treated WT mice developed lesions and prolapses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c8c38a3-55d6-4130-9a45-bd8a8c92a243",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Safety: TSHA-102 did not cause adverse behavioral side effects in WT mice",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5538f20-a2e3-4a39-8b98-04a14345b4a2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 66,
      "from": 31,
      "beatId": "a2d2f153-e121-48a0-8c8f-2d7d544ceb56",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, presenting the company's plans for clinical and commercial development.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 28,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "b03fcf84-5a66-46c7-b35a-c62163b814de",
      "evidence": "The deck presents a clear aha moment, highlighting the importance of regulated expression of MECP2.",
      "position": 1,
      "objective": "Understand the need for regulated expression of MECP2 in Rett syndrome",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}